Key Takeaways:
- Kazia priced 2.58 million ADSs at $15.50, raising about $40 million gross.
- Series A and B warrants could add $80 million if breast cancer readouts hit.
- Proceeds fund paxalisib trials in triple-negative and HR+/HER2- breast cancer.
Quay lại
Kazia Therapeutics prices $40 million offering to fund breast cancer trials
Kazia Therapeutics priced a $40 million public offering of American Depositary Shares and milestone-linked warrants, with up to $80 million more available if investors exercise the instruments, to fund paxalisib trials in advanced breast cancer.
"The combined public offering price for each ADS and accompanying warrants is $15.50," Kazia said in a statement, with the deal expected to close on or about Aug. 31. Leerink Partners and Guggenheim Securities are joint bookrunning managers, with BTIG and Needham & Company as lead managers and Laidlaw & Company (UK) Ltd. as co-manager.
The offering comprises 2.58 million ADSs, each representing 500 ordinary shares, plus Series A warrants exercisable at $17.825 per ADS and Series B warrants at $19.375. The Series A warrants expire 30 days after the company's Stage IV triple-negative breast cancer data readout, expected in the second half of 2027, or the five-year anniversary of issuance; the Series B warrants are tied to an HR+/HER2- breast cancer readout expected in the first half of 2028.
The capital extends Kazia's runway to carry paxalisib through two value-defining clinical milestones, but the warrant structure could add roughly 4.3 million ADSs of dilution if fully exercised. Kazia, based in Sydney, intends to use net proceeds primarily for clinical development of paxalisib across breast cancer and other oncology indications, plus working capital.
Paxalisib's Expanding Breast Cancer Footprint
Paxalisib, a brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway licensed from Genentech in late 2016, has been the subject of more than 15 clinical trials. A completed Phase 2/3 study in glioblastoma, GBM AGILE, was reported in 2024, and Kazia is in discussions to design a pivotal registrational study for standard approval. The drug has drawn early interest in breast cancer: the company previously reported a 100 percent clinical benefit rate in the initial six patients treated for advanced triple-negative breast cancer.
The offering's warrant structure ties investor upside directly to those readouts. Series A warrants, priced at 115 percent of the offering price, convert on the TNBC data; Series B warrants, at 125 percent, convert on the HR+/HER2- data. If both are exercised in full, Kazia would receive additional gross proceeds of about $80 million before expenses.
Cash Runway and Pipeline Depth
Kazia's pipeline extends beyond paxalisib. The company is developing EVT801, a small-molecule VEGFR3 inhibitor licensed from Evotec in April 2021, and two preclinical programs: NDL2, an intracellular PD-L1 protein degrader, and MSETC, a SETDB1 inhibitor aimed at restoring immune signaling in tumors resistant to checkpoint inhibitors. Paxalisib holds FDA Orphan Drug Designation for glioblastoma and diffuse intrinsic pontine glioma, plus Fast Track Designation for glioblastoma and solid tumor brain metastases.
The financing arrives as Kazia trades on the Nasdaq under the ticker KZIA, with the offering made under an effective Form F-3 registration statement. The tranched structure gives the company flexibility to raise capital in stages tied to clinical progress, though investors will weigh the dilution against the potential for data-driven re-rating. The TNBC readout, expected in the second half of 2027, is the first catalyst that would trigger the Series A warrant exercise window.
This article is for informational purposes only and does not constitute investment advice.
